Antiplatelet drugs are routinely used for the prevention and treatment of thrombosis, but also carry an inherent increased risk of bleeding. In this Review, McFadyen and colleagues assess the differences between thrombosis and haemostasis in the context of currently available antiplatelet drugs as well as novel antiplatelet agents that are entering preclinical and early-phase clinical testing.
- James D. McFadyen
- Mathieu Schaff
- Karlheinz Peter